The gut-specific homeotic transcription factor Cdx2 is a crucial regulator of intestinal development and homeostasis, which is downregulated in colorectal cancers (CRC) and exhibits a tumor suppressor function in the colon. We have previously established that several endodermal transcription factors, including HNF4a and GATA6, are involved in Cdx2 regulation in the normal gut. Here we have studied the role of HNF4a in the mechanism of deregulation of Cdx2 in colon cancers. Crossing Apc D14/ þ mice prone to spontaneous intestinal tumor development with pCdx2-9LacZ transgenic mice containing the LacZ reporter under the control of the 9.3-kb Cdx2 promoter showed that this promoter segment contains sequences recapitulating the decrease of Cdx2 expression in intestinal cancers. Immunohistochemistry revealed that HNF4a, unlike GATA6, exhibited a similar decrease to Cdx2 in genetic (Apc min/ þ and Apc D14/ þ ) and chemically induced (Azoxymethane (AOM) treatment) models of intestinal tumors in mice. HNF4a and Cdx2 also exhibited a comparable deregulated pattern in human CRC. Correlated patterns were observed between HNF4a and Cdx2 in several experimental models of human colon cancer cell lines: xenografts in nude mice, wound healing and glucose starvation. Furthermore, Cdx2 decreased by knocking down HNF4a in human colon cancer cells using siRNA and in the colon of mice conditionally knocked out for the Hnf4a gene in the adult intestine (Hnf4a f/f ;VilCre ERT2 mice). Finally, the conditionally knocked out mice Hnf4a f/f ;VilCre ERT2 treated with the carcinogen AOM developed colorectal tumors earlier than wild-type mice, as previously reported for mice with a reduced Cdx2 expression. In conclusion, this study provides evidence that the downregulation of HNF4a is an important determinant of the reduced expression of the Cdx2 tumor suppressor gene in intestinal cancers. Consistently, similar to Cdx2, HNF4a exerts a tumor suppressor function in the colon in that its loss of function facilitates tumor progression.
INTRODUCTION
A complex network of genes contributes to the constant renewal of the intestinal epithelium. Among them, the Cdx2 homeotic gene is essential during development 1 and homeostasis, 2, 3 as it controls the organization of the stem cell niche, provides intestinal identity to stem cells and participates in the cell-autonomous differentiation of the gut epithelium. Besides its role in homeostasis, Cdx2 is also involved in colorectal cancers (CRC). Indeed, its expression is altered in CRC and becomes reduced and heterogeneous in relation to the tumor grade. [4] [5] [6] This reduction facilitates tumor progression and stimulates migration and dissemination of colon cancer cells, [7] [8] [9] which led to attribute a tumor suppressor function to Cdx2 in the gut.
Several studies have addressed the mechanisms of Cdx2 alteration in CRC. It does not result from allelic loss or gene mutation, 6 suggesting rather an altered regulation. Indeed, the gene expression is downregulated in colon cancer cells by oncogenic activation of the Wnt, Ras and PI3K pathways. [10] [11] [12] However, the transcriptional mechanisms relaying the decline of Cdx2 in CRC remain largely elusive. We have previously studied the Cdx2 promoter during intestinal development and homeostasis using transgenic and molecular approaches. 13 The proximal promoter is sufficient to recapitulate the pattern of Cdx2 during embryonic development; however, sustained and tissue-specific expression in the adult gut requires far upstream sequences. These include a phylogenetically conserved segment located about 8.5 kb upstream of the Cdx2 transcription unit that concentrates putative binding sites for several transcription factors such as HNF4a and GATA6, which synergistically stimulate the Cdx2 promoter.
HNF4 belongs to the superfamily of nuclear receptors, one of the largest families of transcription factors. In mammals, two genes encode the different HNF4a (NR2A) and HNF4g (NR2A2) isoforms. HNF4a is expressed in the liver, stomach, pancreas, kidney and intestine, 14, 15 whereas HNF4g is mostly intestinal.
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In vivo and in vitro studies have shown that HNF4a has pleiotropic roles in the liver. 17 In the gut, HNF4a has important functions and is a key regulator of enterocytic markers. 18, 19 Conditional knockout of the Hnf4a gene in the mouse embryonic colon causes lethality because of the perturbation of organogenesis, cytodifferentiation and gene expression, 20 and its ablation in the adult intestine reveals its involvement in homeostasis, cell architecture and barrier function. 21 This is consistent with a protective role attributed to HNF4a against inflammatory bowel diseases. 22 Although the role of HNF4a is well described in the normal gut, its involvement in CRC is less clear. As HNF4a binds and regulates the Cdx2 promoter in normal intestinal cells, 13, 23 and as the expression of Cdx2 is altered in CRC with an impact on tumor progression, the aim of this study was to address whether HNF4a is also a determinant for the deregulation of Cdx2 in colon cancers, as well as its relevance in these cancers.
RESULTS
The 9.3-kb Cdx2 promoter contains elements for gene deregulation during colon carcinogenesis Cdx2 expression is reduced and heterogeneous in human CRC and also strongly compromised in genetic (Apc min/ þ or Apc D14/ þ mice) and chemically induced (Azoxymethane (AOM) treatment) models of intestinal cancers in mice. 6, 7, 24 We have previously reported that a genomic segment of 9.3 kb, upstream of the Cdx2 transcription unit, contains regulatory elements required for tissue-specific expression throughout adulthood in the normal gut. 13 Here we wondered whether the sequences mediating the decline of Cdx2 in tumors are also contained within this fragment.
For this purpose, pCdx2-9LacZ transgenic mice in which the LacZ reporter is placed under the control of the 9.3-kb promoter of Cdx2 13 were crossed with Apc D14/ þ mice prone to spontaneous development of intestinal tumors. 25 The 9.3-kb Cdx2 promoter is mostly active in the pericecal region and proximal colon, 13 whereas Apc D14/ þ mice develop adenomas in the proximal small intestine and precancerous aberrant crypt foci in the colon. 25 Yet a malignant evolution of colonic lesions occurs when Apc D14/ þ mice are subjected to a proinflammatory stress. 26 Therefore, pCdx2-9LacZ;Apc D14/ þ mice were given DSS in the drinking water for 5 days, leading to the development of tumors in the proximal colon, and these tumors were analyzed 8 weeks later for LacZ and Cdx2 expression (Figure 1 ). Whole-mount staining of b-galactosidase activity showed that, in contrast to the normal adjacent mucosa, the tumors did not express LacZ, except for few normal glands embedded into the mass of the polyps. Histological sections co-immunostained with Cdx2 antibody confirmed the progressive decrease of Cdx2 protein expression together with the reduction of Cdx2 promoter activity (LacZ staining) in the tumors of DSS-treated pCdx2-9LacZ;Apc D14/ þ mice. The parallel decrease of promoter activity and protein expression of Cdx2 indicates that the 9.3-kb promoter contains regulatory sequences targeted by the oncogenic pathway(s) involved in the malignant process in Apc D14/ þ mice.
Comparison of the profiles of Cdx2, HNF4a and GATA6 in intestinal tumors The 9.3-kb promoter contains an upstream regulatory segment required for sustained expression of Cdx2 in the adult gut epithelium that synergistically responds to the endodermal transcription factors HNF4a and GATA6. 13 To address whether these factors could have a role in the decrease of Cdx2 expression in intestinal tumors, we compared their expression patterns in three models of intestinal cancers in mice (Figure 2a ): the Apc D14/ þ and Apc min/ þ mice that spontaneously develop adenomas in the small intestine, 25, 27 and mice treated with a chemical carcinogen, AOM, that develop adenocarcinomas in the distal colon about 30 weeks after repeated administration of the carcinogen. 7 Immunohistochemical staining indicated that Cdx2 expression was impaired in the small intestinal and colon tumors present in the three mouse models. HNF4a was altered similar to Cdx2, with an obvious decrease in malignant cells compared with the adjacent normal epithelium. Unlike Cdx2 and HNF4a, GATA6 did not show such a decrease. Therefore, it appears that, among the factors synergistically involved in the control of the Cdx2 promoter, HNF4a but not GATA6 shows an altered profile consistent with the perturbed expression of Cdx2 in intestinal tumors.
To address whether there is also a correlation between HNF4a and Cdx2 in humans, we first analyzed these two proteins in a collection of 35 human colorectal adenomas previously described. 28 Compared with the normal mucosa that exhibits a strong nuclear staining of Cdx2 and HNF4a, the nuclear staining became weaker or very low ( Figure 2b ) in adenomas, together with the appearance of cytoplasmic staining. These altered patterns were similar for Cdx2 and HNF4a in all adenomas. Next, we compared Cdx2 and HNF4a in 12 samples of moderately to well-differentiated sporadic CRC known to exhibit a heterogeneous expression of Cdx2. 6 These samples correspond to primary adenocarcinomas of chromosomal instability type at the stage II or higher in the American Joint Committee on Cancer classification. 6 Cdx2 is heterogeneous in these samples, especially at the tumor edge containing the invasive cells. 5, 6 At the invasive front (Figure 2c ), clusters of tumor cells keeping a relatively high level of Cdx2 also retained HNF4a expression, whereas stretches of cells with a low expression of Cdx2 were similarly low for HNF4a. This is consistent with the previously reported dysregulation of HNF4a promoters' activities in human CRC. 29 These data indicate Figure 1 . Reduction of activity of the 9.3-kb Cdx2 promoter in mouse intestinal tumors. pCdx2-9LacZ;Apc D14/ þ mice aged 3 months were treated with 5 kDa and then with 40 kDa Dextran Sulfate Sodium (DSS; MP Biomedicals, Illkirch, France) at 3% in drinking water during 5 days, as previously described. 36 Eight weeks later, the cecum and proximal colon were harvested and processed for whole-mount staining of b-galactosidase activity. 13 Whole-mount stained samples were sectioned (5 mm) and used for immunohistochemistry with anti-Cdx2 antibody (CDX2-88, BioGenex, San Ramon, CA, USA, dilution 1/500). 13 (a) HT29 cells were cultured in vitro or xenografted under the skin of nude mice and then plated back in culture in vitro for 1 passage, 2 passages or 3 passages, as described. 30 The levels of HNF4a (open boxes) and Cdx2 (gray boxes) mRNAs were determined by RT-qPCR as described 9 using the Gene Specific Assays Hs00230919_m1 for Cdx2, Hs01023298_m1 for HNF4a and #4333769F for TBP (Applied Biosystems, Carlsbad, CA, USA). Data are given as ±s.e.m., *Po0.01; **Po0.001. (b) HT29 cells were grafted orthotopically in the cecum wall or heterotopically under the skin of nude mice as described in, 9 and tumor sections were immunostained for HNF4a and Cdx2 proteins, as described. 13 Bars are 100 mm. and Apc D14/ þ mice and colon tumors of AOM-treated mice were stained with haematoxylin-eosin (HE) for histology and immunostained with the antibodies against Cdx2, HNF4a (sc8987, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, dilution 1/500) and GATA6 (AF1700, RD systems, Minneapolis, MN, USA, dilution 1/500). The boxes in the HE stains correspond to the regions shown below after immunochemical staining. Bars are 500 mm for the HE staining of Apc min/ þ and Apc D14/ þ mice and 100 mm for the HE staining of the AOM-treated mouse and all immunostainings of HNF4a, Cdx2 and GATA6. (b) Correlation between Cdx2 and HNF4a in human colorectal adenomas. The left panels correspond to normal colon mucosa, and the middle and right panels illustrate the Cdx2 and HNF4a patterns in two adenomas exhibiting, respectively, a relatively high level of both proteins in the nuclei and a strongly reduced expression of these proteins. Bars are 100 mm. (c) Heterogeneous expression of HNF4a and Cdx2 in human colon adenocarcinomas. Human samples were co-immunostained for Cdx2 (red) and HNF4a (green). The pictures illustrate the invasive area where structures with a low expression of both proteins are indicated with white arrowheads and those with a relatively high coexpression with a white arrow. Bars are 50 mm.
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Functional correlation between HNF4a and Cdx2
The parallel between HNF4a and Cdx2 in human CRC and in mouse models of intestinal tumors, together with our previous molecular demonstration that HNF4a is an important regulator of the Cdx2 promoter, 13 prompted us to investigate whether such correlation also exists in cellular experimental models involving human CRC cell lines.
Human colon cancer cells HT29 express Cdx2 at a very low level in culture, and this can be stimulated when cells are grafted heterotopically under the skin of nude mice; moreover, when cells from subcutaneous xenografts exhibiting a high level of Cdx2 are cultured back in vitro, the expression of Cdx2 progressively drops again. 30 Under these conditions, reverse transcriptionquantitative polymerase chain reaction (RT-qPCR) indicated that the levels of HNF4a mRNA correlated with those of Cdx2 (Figure 3a) . We also previously reported that Cdx2 is strongly expressed in subcutaneous xenografts of HT29 cells in nude mice, whereas it is much lower when cells are orthotopically grafted in the cecum wall. 30 As shown by immunohistochemistry, the HNF4a protein followed the same pattern as Cdx2 in these orthotopic and heterotopic xenografts (Figure 3b ).
The second model corresponds to the wound healing of a confluent monolayer of human colon cancer cells Caco2-TC7. Caco2-TC7 cells express Cdx2 at a relatively high level in standard conditions of culture, and this expression drops in migrating cells at the wound edge compared with confluent cells. 9 As for Cdx2, HNF4a expression was reduced in migrating cells from the wound edge compared with the confluent monolayer, as shown by immunofluorescence and RT-qPCR (Figure 3c ).
HNF4a is an important regulator of the metabolic cell response to glucose, and it is itself regulated by glucose in hepatocytes. 31 Thus, we addressed whether glucose also controls the level of ;VilCre ERT2 mice (KO) were injected intraperitoneally for 5 days with Tamoxifen at 600 mg/15 ml as described. 21 Samples from the distal colon were collected and processed for haematoxylin-eosin (HE), HNF4a and Cdx2 immunostaining. Bars are 50 mm. In addition to the specific nuclear staining, the Cdx2 monoclonal antibody also stains unspecifically immune cells within the lamina propria. (b) Colorectal tumors induced by AOM in Hnf4a-knockout mice. Colorectal tumors were induced by injecting Hnf4a-KO mice (n ¼ 8) and control mice (n ¼ 7) intraperitoneally with AOM at 10 mg/kg weekly for 5 weeks. 7 Colons were harvested 8-12 weeks after the last injection, and macroscopically visible tumors were counted after methylene blue staining and processed for histology and immunohistochemistry. Only Hnf4a-KO mice presented tumors at this stage (see Table 1 ). A representative adenocarcinoma was stained with HE, immunostained for HNF4a, Cdx2, Phospho-Histone-3 and b-catenin; alcian blue stained mucins. Arrowheads show adenomatous glands and asterisks point to carcinomatous areas. Bar is 500 mm for HE and 100 mm for other stainings.
HNF4a in colon cancer cells. To this end, Caco2-TC7 cells were cultured for 48 h in the medium containing 4 g/l of glucose and then shifted to a medium containing 1 g/l glucose. As illustrated in Figure 3d , this led to a rapid decline of the HNF4a protein already visible 12 h after the glucose shift. Of note, this condition also resulted in a decrease of Cdx2 protein, but this occurred with a delay compared with HNF4a.
Finally, we investigated the outcome of knocking down HNF4a on Cdx2 expression by transfecting Caco2-TC7 cells with siRNA@HNF4a. Even if the siRNA only produced an B3-fold reduction in the level of HNF4a protein, it nonetheless induced a 5-fold decrease in Cdx2 protein (Figure 3e) . Reciprocally, in HCT116 cells characterized by a very low endogenous expression of both HNF4a and Cdx2, the transfection of an HNF4a-encoding plasmid stimulated the endogenous expression of Cdx2 by 8.5-fold (Figure 3f) .
Together, these data strongly indicate that the level of HNF4a present in human colon cancer cells is an important determinant of the rate of Cdx2 expression. This is fully in line with our previous findings that HNF4a binds and activates a reporter plasmid containing the Cdx2 promoter. 13 Susceptibility of intestine-specific Hnf4a-deficient mice to colon carcinogenesis The Cdx2 homeobox gene is not only a major factor of intestinal morphogenesis and homeostasis [1] [2] [3] but also a determinant of the progression of CRC, as its reduced expression in Cdx2 þ / À mice accelerates the development of colorectal tumors in animals treated with the colon carcinogen AOM. 7 Having shown above that the level of HNF4a is modified in CRC and that these modifications induce changes of Cdx2 expression, we checked whether the alteration of HNF4a in the gut also has an impact on CRC.
For this purpose, Hnf4a f/f mice 32 were crossed with VilCre ERT2 mice. 33 Analysis of the colon of Hnf4a f/f ;VilCre ERT2 mice treated with Tamoxifen at the adult stage (referred thereafter as to KO mice) revealed a mosaic pattern of knockout of the Hnf4a gene. Importantly, the epithelial areas where Hnf4a was efficiently knocked out exhibited a strong reduction of Cdx2 expression, corroborating that HNF4a is a regulator of the Cdx2 gene in vivo in the colon (Figure 4a ). As previously reported, mice conditionally knocked out for Hnf4a in the gut do not spontaneously develop tumors. 21 Thus, as performed earlier with Cdx2 þ / À mice, 7 we promoted the oncogenic process by treating Hnf4a KO mice and Hnf4a f/f mice as controls with AOM. This treatment is known to induce distal colon adenomas and adenocarcinomas after 25-30 weeks in controls but much earlier in Cdx2 þ / À mice. 7 Therefore, we compared the presence of lesions in the distal colon of Hnf4a KO and control mice 8-12 weeks after AOM treatment. As shown in Table 1 , although no lesion was detected in control mice (n ¼ 7), a total of 12 tumors was recorded in Hnf4a KO mice (n ¼ 8) (Figure 4b ). These tumors were 1-3 mm in diameter. Seven of the eight Hnf4a KO animals presented at least one tumor, and the average of tumors per mouse was 1.5. Histological examination showed that they corresponded to adenomas and in situ adenocarcinomas, characterized by a concomitant loss of HNF4a and Cdx2, a loss of cytodifferentiation, in particular goblet cells, a high rate of cell proliferation and cytoplasmic translocation of b-catenin (Figure 4b ).
In conclusion, this study demonstrates that, beyond its role during gut development and homeostasis, HNF4a, but not GATA6, is an important determinant of the deregulation of the homeobox gene Cdx2 in CRC. This is on the basis of the observation that HNF4a and Cdx2 exhibit similar patterns of alteration in human CRC, as well as in murine models of intestinal tumors, and that changing experimentally the level of HNF4a in human colorectal cell lines modifies the expression of Cdx2 in the same way.
Consequently, in accordance with the anti-tumor role attributed to Cdx2, 7 we provide evidence that the reduction of HNF4a accelerates colorectal tumor progression, making this gene a new candidate with a tumor-suppressive function in the colon. This is at odds with a previous study conducted using Apc þ / À mice 34 but in line with the tumor-suppressive role attributed to HNF4a in human hepatocellular carcinoma. 35 The reason for the discrepancy between our results and those from Darsigny et al. 34 is not clear but could rely on the differences between the Apc þ / À and AOM models. For instance, Apc þ / À mice are not a model of CRC as they mainly develop tumors in the small intestine, which are rare in humans, whereas the AOM model produces distal colon tumors, in accordance with the major site of tumor development in humans. Another difference is that Apc þ / À mice are a model of Apc-dependent cancerogenesis, whereas AOM rather induce K-ras and b-catenin mutations. Finally, in the model used by Darsigny et al., 34 the Hnf4a knockout is already induced in the embryonic endoderm, allowing compensatory mechanisms to take place during further intestinal development, whereas Hnf4a was deleted only at the adult stage in our study. Together, our results and those previously reported 21 indicate that the loss of HNF4a is not tumorigenic by itself, but that it enhances the cell proliferation rate, which then has an impact on the outgrowth of tumors induced by an oncogenic event. The dysfunction of HNF4a in CRC may not only have an impact on the general metabolism and behavior of cancer cells but also act on Cdx2 expression, which is essential for intestinal homeostasis 2, 3 and has a tumor-suppressive function. 21 ). Mice were induced for colon cancer by AOM treatment (5 weekly injections of AOM at 10 mg/kg) or injected with 0.9% NaCl. Colons were harvested 8-12 weeks after the last injection of AOM or NaCl, and analyzed for the presence of adenoma and adenocarcinoma lesions.
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